Pharnext completes Paris IPO, raising €30.9m to fund advanced clinical trials
Pharnext, a French biopharmaceutical company specialising n treatments for neurological conditions such as Alzheimer’s disease, has successfully completed its IPO on the Alternext market of Euronext Paris.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts